COMMUNIQUÉS West-GlobeNewswire

Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/11/2025
Topline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming weeks (Q4 2025) Pending the results of the topline data from the HOPE-3 [...]
Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights
10/11/2025
Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta on-track for around the end of 2025 Cash of $48.7 million as of September 30, 2025, expected to support operations into 2027 LONDON, [...]
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
10/11/2025
BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR) (Vor Bio), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced that it has [...]
MIMEDX to Participate in Upcoming Investor Conferences
10/11/2025
MARIETTA, Ga., Nov. 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences [...]
TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
10/11/2025
Fireside chat scheduled for Wednesday November 12, 2025 at 10:00 AM ET NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and [...]
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
10/11/2025
One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-up Consistent trend in disease stability or improvement in multiple measures of cardiomyopathy [...]
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
10/11/2025
COPENHAGEN, Denmark, November 10, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4,94 [...]
Regional Health Properties, Inc. Reports Sale of Skilled Nursing Facility
10/11/2025
Atlanta, GA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional,” the “Company,” “we,” “us” or “our”) (OTCQB: RHEP) (OTCQB: RHEPA) (OTCQB: RHEPB) (OTCQB: RHEPZ) today announced the completion [...]
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/11/2025
REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today [...]
Burn Blend 2025 | Effective Weight Loss Supplement Read Benefits, Ingredients Lunch Burn Blend Canada & Australia
10/11/2025
Burn Blend is a natural Weight Loss Supplement that combines nature’s most effective ingredients to support focus, endurance, and metabolism. Read BurnBlend consumer reports. New York City, Nov. 10, 2025 (GLOBE NEWSWIRE [...]
TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Third Quarter 2025 Financial Results on November 14, 2025
10/11/2025
FREDERICK, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report [...]
Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight
10/11/2025
TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets artificial intelligence (“AI”)- [...]
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/11/2025
SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock [...]
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
10/11/2025
Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025 More than half of the patients required [...]
Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights
10/11/2025
Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia set to launch in November Tonmya is the first new FDA-approved medicine for fibromyalgia in more than 15 years Cash and cash equivalents [...]
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
10/11/2025
Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study Aligned with the U.S. Food and Drug Administration (FDA) on an analytical approach to establish comparability of a high [...]
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
10/11/2025
Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital from Medtronic and [...]
LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline
10/11/2025
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) today announced a reminder to LAVA shareholders related to the proposed transaction with XOMA [...]
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance
10/11/2025
Delivered ~ 21% worldwide revenue growth, ~ 5% adjusted EBITDA margin, and positive cash from operating activities in the quarter Third Quarter 2025 Financial Highlights (all comparisons are to the prior year period) [...]

Pages